Editas Medicine Announces First Quarter 2016 Results and Update
May 16, 2016 07:30 ET
|
Editas Medicine, Inc.
Advancing pipeline and platform demonstrated by data presented at medical and scientific conferences as well as achievement of Juno Therapeutics milestone Strengthened effort to develop medicines...
Editas Medicine to Host Conference Call Discussing First Quarter 2016 Corporate Update and Results
May 09, 2016 08:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., May 09, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday,...
Editas Medicine Achieves Milestone under its Collaboration with Juno Therapeutics
May 04, 2016 07:30 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today that it has achieved a $2.5 million milestone under its...
Editas Medicine Announces Presentations at Upcoming Scientific Conferences
April 27, 2016 16:01 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., April 27, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that Editas scientists will present data from its...
Editas Medicine to Present at Deutsche Bank 41st Annual Health Care Conference
April 27, 2016 08:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., April 27, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview at the Deutsche...
Editas Medicine to Present at 15th Annual Needham Healthcare Conference
April 06, 2016 16:01 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., April 06, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview at the 15th...
Editas Medicine Reports Fourth Quarter and Full Year 2015 Financial Results
March 30, 2016 08:00 ET
|
Editas Medicine, Inc.
Well-positioned to advance multiple programs and continue expansion of genome editing platform Cash balance of approximately $230 million funds diversified pipeline Executive team and board of...